stoxline Quote Chart Rank Option Currency Glossary
  
Bright Minds Biosciences Inc. (DRUG)
45.18  -0.38 (-0.83%)    02-12 19:24
Open: 44.46
High: 46.14
Volume: 23,152
  
Pre. Close: 45.56
Low: 40.1
Market Cap: 316(M)
Technical analysis
2025-02-12 4:44:13 PM
Short term     
Mid term     
Targets 6-month :  54.44 1-year :  63.58
Resists First :  46.61 Second :  54.44
Pivot price 37.85
Supports First :  35.23 Second :  28.2
MAs MA(5) :  44.99 MA(20) :  37.11
MA(100) :  33.52 MA(250) :  14.13
MACD MACD :  2.1 Signal :  0.7
%K %D K(14,3) :  94.9 D(3) :  96.2
RSI RSI(14): 67.2
52-week High :  79.01 Low :  0.93
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DRUG ] has closed below upper band by 19.1%. Bollinger Bands are 23.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 46.2 - 46.48 46.48 - 46.69
Low: 39.49 - 39.81 39.81 - 40.04
Close: 44.71 - 45.23 45.23 - 45.6
Company Description

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Headline News

Thu, 23 Jan 2025
Piper Sandler sets $93 target for Bright Minds Biosciences stock - Investing.com

Tue, 31 Dec 2024
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq

Mon, 04 Nov 2024
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - Yahoo Finance

Fri, 18 Oct 2024
Bright Minds Bio soars on US$35M private placement; up 5,400% in 5 days - Mugglehead

Fri, 18 Oct 2024
Bright Minds stock gains post-private placement (DRUG:NASDAQ) - Seeking Alpha

Wed, 16 Oct 2024
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 7 (M)
Shares Float 1 (M)
Held by Insiders 27.2 (%)
Held by Institutions 44.2 (%)
Shares Short 221 (K)
Shares Short P.Month 265 (K)
Stock Financials
EPS -0.45
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.37
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -28.9 %
Return on Equity (ttm) -51.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -1 (M)
Stock Valuations
PE Ratio -100.41
PEG Ratio 0
Price to Book value 32.97
Price to Sales 0
Price to Cash Flow -122.41
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android